Revance Therapeutics (RVNC) Misses Q2 EPS by 17c, misses on revenue

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.80), $0.17 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $58.13 million versus the consensus estimate of $58.88 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c